Anti-Fungal Drugs Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)

The Antifungal Drugs Treatment Market is segmented by Drug Type (Echinocandins, Azoles, Polyenes, Allylamines, and Other Drug Types), Indication (Aspergillosis, Dermatophytosis, Candidiasis, and Other Indications), Dosage Form (Powder, Ointments, Tablets, and Other Dosage Forms), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America).

Anti-Fungal Drugs Market Size

Anti-fungal Drugs Market Summary
share button
Study Period 2020 - 2029
Base Year For Estimation 2023
CAGR 3.50 %
Fastest Growing Market Asia Pacific
Largest Market North America
Market Concentration Low

Major Players

Anti-fungal Drugs Market Major Players

*Disclaimer: Major Players sorted in no particular order

setting-icon

Need a report that reflects how COVID-19 has impacted this market and its growth?

Anti-Fungal Drugs Market Analysis

The anti-fungal drugs market is expected to register a CAGR of 3.5% during the forecast period.

  • The anti-fungal drug market is expected to experience significant growth and register a CAGR of 3.5% during the forecast period. The COVID-19 pandemic profoundly affected the market, with import and export operations being limited due to closures, resulting in shortages and unavailability of consumer goods and supplies. However, emerging reports and research indicated that a significant number of patients with severe COVID-19 infections required intensive care and were fighting another fatal infection, such as aspergillosis, caused by Aspergillus fungus.
  • According to a study published in the Journal of Microbiology, Immunology, and Infection in February 2021, invasive pulmonary aspergillosis (IPA) incidence ranged from 19.6% to 33.3% among the studied population. Thus, researchers have found that patients with COVID-19 were at greater risk of pulmonary infections caused by fungal respiration, creating a demand for anti-fungal drugs during the later phases of the pandemic. Consequently, despite the short-term decline in the number of drugs and supply chain disruptions, the increasing fungal infections among COVID-19 patients had a considerable impact on the market, which is expected to continue to gain traction during the analysis period.
  • The major factors contributing to the growth of the anti-fungal drug market include increased awareness of many fungal infections, rising numbers of over-the-counter (OTC) anti-fungal drugs, and increased use of antimicrobial drugs in developing countries. The growing popularity of OTC drugs such as clotrimazole, econazole, ketoconazole, miconazole, and amorolfine has resulted in many patients using OTC drugs. An increase in onychomycosis cases, a fungal infection of the fingers and toes, is also expected to contribute to the market growth. For instance, according to the data updated by CDC in September 2022, onychomycosis may affect up to 14% of the general population in the world, and fungal toenail infections are more common than fungal fingernail infections.
  • Moreover, excessive glucose can lead to high cellular damage, resulting in several infectious and non-infectious skin disorders. Therefore, diabetes patients are more susceptible to various fungal infections, and onychomycosis is one of the major infections among the target population. According to an article published in the Journal of Fungi in August 2022, when a group of people was studied for skin and nail disorders in diabetic patients, onychomycoses were found common in critically ill diabetic patients.
  • Dermatophytes were found to be the commonest cultural isolates (50%), followed by yeasts and molds in 30.8% and 19.2%, respectively, of the studied diabetes patients. Hence, the high burden of diseases among the target population is expected to increase the demand for anti-fungal and contribute to the overall growth of the studied market over the forecast period.
  • However, increasing resistance to anti-fungal drugs and the side effects of these drugs are anticipated to hinder their adoption and demand, thereby restraining the market's growth.

Anti-Fungal Drugs Market Trends

Azoles Segment Expected to Witness Significant Growth During the Forecast Period

  • The azole group of compounds are antifungal agents that have greatly expanded therapeutic options for treating systemic fungal infections. Research in the field of fungal drugs is growing rapidly, thanks to the development of new antifungal drugs using the azole group. Synthetic azoles and semi-synthetic compounds are widely used for fungal infections, and as a result, the segment is expected to experience significant growth over the analysis period.
  • Azole group drugs are used to treat a variety of fungal infections, including thrush, yeast infections, candidiasis, aspergillosis, tinea versicolor, athlete's foot, jock itch, ringworm, systemic mycosis, and seborrheic dermatitis. The azole antifungal group includes two phases: triazoles (fluconazole, itraconazole, voriconazole, posaconazole, and isavuconazole) and imidazoles (ketoconazole).
  • Triazoles have a wide range of applications in the treatment of external fungal infections and systemic infections. The azole group provides a broad spectrum of activity and improved safety standards. These medications have fewer side effects, fewer drug interactions, and improved absorption and distribution properties. These benefits of azoles have contributed to their superiority over other components, further fueling the growth of the segment.
  • In addition, the development and innovation of such potential drugs promote the competitiveness of the pharmaceutical market. In October 2021, Intas Pharmaceuticals Limited launched an innovative antifungal drug, Super Bioavailable Itraconazole-SB 100 mg, under the brand name Itaspor-SB Forte/Subawin.
  • Furthermore, in June 2021, Cadila Pharmaceuticals introduced a new triazole antifungal drug, Posaconazole, which is effective against a wide range of invasive fungal diseases. The drug has also been recommended as a second-line treatment for Mucormycosis. Such advancements are expected to drive the growth of the segment during the forecast period.
Anti-fungal Drugs Market: Estimated Annual Burden of Fungal Infections (in thousands), By Type, Global, 2021

North America Expected to Hold a Significant Share of the Market

  • North America holds a significant share of the market under study and is expected to maintain its strong position during the analysis period. This growth can be attributed to factors such as the increasing burden of fungal infections among the target population and rising company activities for product development across the countries in the region.
  • The United States is one of the most economically developed countries in the region, among other countries such as Canada and Mexico. However, fungal infections in the country have presented challenges to health authorities. According to data updated by the Centers for Disease Control and Prevention (CDC) in June 2022, Candida was a common cause of blood-related infections in the United States, and a few drug-resistant strains were also prevalent in the country. Hence, there is a growing need for anti-fungal drugs in the United States.
  • Additionally, there have been recent outbreaks of fungal infections in Canada, which have fueled the need for anti-fungal drugs for treatment. For example, in September 2022, as per a press release by Quebec's health ministry, the department dispatched infection control teams to Pierre Boucher Hospital in Longueuil to combat the first-ever outbreak of a potentially deadly fungus, "Candida auris," in Quebec. Candida auris is a type of yeast that can cause severe illness. When it is found in any healthcare setting, it is more dangerous for admitted patients and caregivers. These instances and the burden of infections have created a potential need for the availability of anti-fungal drugs and are expected to contribute to the growth of the studied market in the region.
  • Moreover, product approvals and launches by market players are further creating competition in the market. For instance, in June 2021, Scynexis announced the FDA approval of Brexafemme for the treatment of vaginal yeast infections. In addition, in January 2021, Sandoz Canada Inc. launched PrSandoz Posaconazole, making Sandoz the first company to offer posaconazole generics on the Canadian market. Sandoz Posaconazole is used to treat Aspergillus fungal infections and to prevent fungal infections caused by Aspergillus and Candida, especially in oncology patients with a history of stem cell transplant. Such company activities and the burden of fungal infections are anticipated to accelerate the growth of the studied market in the region over the forecast period.
: Anti-fungal Drugs Market - Growth Rate by Region

Anti-Fungal Drugs Industry Overview

The analyzed market is moderately competitive, primarily due to the presence of a limited number of smaller players and several major industry players. The market participants are actively engaged in launching new products and obtaining approvals for them, which is anticipated further to intensify the competitive environment within the studied market. Among the significant market players are Abbott Laboratories, Bayer AG, Astellas Pharma Inc., Glenmark Pharmaceuticals Limited, GSK plc, Merck & Co. Inc., Novartis AG, Pfizer Inc, and others.

Anti-Fungal Drugs Market Leaders

  1. Abbott Laboratories

  2. Bayer AG

  3. Merck & Co., Inc.

  4. Glenmark Pharmaceuticals Limited

  5. GSK plc

*Disclaimer: Major Players sorted in no particular order

Anti-fungal Drugs Market Concentration
bookmark Need More Details on Market Players and Competitors?
Download PDF

Anti-Fungal Drugs Market News

  • June 2022: Apex Labs introduced the advanced Supra Bioavailable Itraconazole 65 and 130 mg capsules, a potent therapeutic option for effectively controlling fungal infections. Supra Bioavailable Itraconazole capsules deliver a higher percentage (90 percent) of active medicine to the biological system at a lesser dose. This advanced preparation also ensures lesser inter-individual variability, which might translate into enhanced efficacy in the management of fungal infections, a statement from the company notified.
  • April 2022: The United States Food and Drug Administration (US FDA) granted approval for VIVJOA (oteseconazole capsules), an azole antifungal indicated to reduce the incidence of recurrent vulvovaginal candidiasis (RVVC) in females. VIVJOA marks the first and only FDA-approved medication for this condition and represents the initial FDA-approved product for Mycovia Pharmaceuticals, Inc. (Mycovia).

Anti-Fungal Drugs Market Report - Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Assumptions and Market Definition

    2. 1.2 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Increasing Awareness about Fungal Infections

      2. 4.2.2 Increasing Number of Antifungal Drugs as Over-the-counter (OTC)

      3. 4.2.3 Rising Consumption of Antifungal Drugs in Developing Regions

    3. 4.3 Market Restraints

      1. 4.3.1 Increasing Resistance to Antifungal Drugs

      2. 4.3.2 Side Effects of Antifungal Drugs and Product Recalls

    4. 4.4 Porter's Five Forces Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION (Market Size by Value - USD Million)

    1. 5.1 By Drug Type

      1. 5.1.1 Echinocandins

      2. 5.1.2 Azoles

      3. 5.1.3 Polyenes

      4. 5.1.4 Allylamines

      5. 5.1.5 Other Drug Types

    2. 5.2 By Indication

      1. 5.2.1 Aspergillosis

      2. 5.2.2 Dermatophytosis

      3. 5.2.3 Candidiasis

      4. 5.2.4 Other Indications

    3. 5.3 By Dosage Form

      1. 5.3.1 Powder

      2. 5.3.2 Ointments

      3. 5.3.3 Tablets

      4. 5.3.4 Other Dosage Forms

    4. 5.4 Geography

      1. 5.4.1 North America

        1. 5.4.1.1 United States

        2. 5.4.1.2 Canada

        3. 5.4.1.3 Mexico

      2. 5.4.2 Europe

        1. 5.4.2.1 Germany

        2. 5.4.2.2 United Kingdom

        3. 5.4.2.3 France

        4. 5.4.2.4 Italy

        5. 5.4.2.5 Spain

        6. 5.4.2.6 Rest of Europe

      3. 5.4.3 Asia-Pacific

        1. 5.4.3.1 China

        2. 5.4.3.2 Japan

        3. 5.4.3.3 India

        4. 5.4.3.4 Australia

        5. 5.4.3.5 South Korea

        6. 5.4.3.6 Rest of Asia-Pacific

      4. 5.4.4 Middle East and Africa

        1. 5.4.4.1 GCC

        2. 5.4.4.2 South Africa

        3. 5.4.4.3 Rest of Middle East and Africa

      5. 5.4.5 South America

        1. 5.4.5.1 Brazil

        2. 5.4.5.2 Argentina

        3. 5.4.5.3 Rest of South America

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 Abbott Laboratories

      2. 6.1.2 Astellas Pharma Inc.

      3. 6.1.3 Bayer AG

      4. 6.1.4 GSK plc

      5. 6.1.5 Glenmark Pharmaceuticals Limited

      6. 6.1.6 Arcadia Consumer Healthcare

      7. 6.1.7 Merck & Co. Inc.

      8. 6.1.8 Novartis AG

      9. 6.1.9 Pfizer Inc.

      10. 6.1.10 SCYNEXIS Inc.

      11. 6.1.11 Mycovia Pharmaceuticals, Inc.

      12. 6.1.12 Apex Laboratories Pvt. Ltd.

    2. *List Not Exhaustive
  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments
bookmark You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

Anti-Fungal Drugs Industry Segmentation

As per the scope of this report, anti-fungal drugs refer to the drugs used/prescribed for the treatment of diseases caused by fungi. 

The anti-fungal drugs market is segmented by drug type (echinocandins, azoles, polyenes, allylamines, and other drug types), indication (aspergillosis, dermatophytosis, candidiasis, and other indications), dosage form (powder, ointments, tablets, and other dosage forms), and geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). 

The report offers the value (in USD billion) for the above segments.

 

By Drug Type
Echinocandins
Azoles
Polyenes
Allylamines
Other Drug Types
By Indication
Aspergillosis
Dermatophytosis
Candidiasis
Other Indications
By Dosage Form
Powder
Ointments
Tablets
Other Dosage Forms
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa
GCC
South Africa
Rest of Middle East and Africa
South America
Brazil
Argentina
Rest of South America
customize-icon Need A Different Region Or Segment?
Customize Now

Anti-Fungal Drugs Market Research FAQs

The Anti-fungal Drugs Market is projected to register a CAGR of 3.5% during the forecast period (2024-2029)

Abbott Laboratories, Bayer AG, Merck & Co., Inc., Glenmark Pharmaceuticals Limited and GSK plc are the major companies operating in the Anti-fungal Drugs Market.

Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).

In 2024, the North America accounts for the largest market share in Anti-fungal Drugs Market.

The report covers the Anti-fungal Drugs Market historical market size for years: 2020, 2021, 2022 and 2023. The report also forecasts the Anti-fungal Drugs Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.

Anti-Fungal Drugs Industry Report

Statistics for the 2024 Anti-Fungal Drugs market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Anti-Fungal Drugs analysis includes a market forecast outlook to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.

close-icon
80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!

Anti-Fungal Drugs Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)